Tenax Therapeutics Inc
TENX13.100USD
+0.280+2.18%
收盘 12/19, 16:00（美东）报价延迟15分钟
77.38M总市值
亏损市盈率 TTM
关于 Tenax Therapeutics Inc 公司
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).
Tenax Therapeutics Inc简介
公司代码TENX
公司名称Tenax Therapeutics Inc
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
员工数量4
证券类型Ordinary Share
年结日Oct 28
公司地址101 Glen Lennox Drive
城市CHAPEL HILL
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编27517
电话19198552100
网址http://www.tenaxthera.com/
公司代码TENX
上市日期Oct 28, 1993
CEOGiordano (Christopher T)
Tenax Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
7.65K
+188.39%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Robyn M. Hunter
Ms. Robyn M. Hunter
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Stuart Rich, M.D.
Dr. Stuart Rich, M.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
7.65K
+188.39%
Dr. Declan Doogan, M.D.
Dr. Declan Doogan, M.D.
Independent Director
Independent Director
2.27K
--
Mr. Gerald T. (Gerry) Proehl
Mr. Gerald T. (Gerry) Proehl
Independent Chairman of the Board
Independent Chairman of the Board
1.67K
--
Mr. Thomas A. (Tom) Mcgauley
Mr. Thomas A. (Tom) Mcgauley
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. June Almenoff, M.D., Ph.D.
Dr. June Almenoff, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Christopher T. (Chris) Giordano
Mr. Christopher T. (Chris) Giordano
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月28日 周五
更新时间: 11月28日 周五
持股股东
股东类型
持股股东
持股股东
占比
Ikarian Capital LLC
15.50%
Janus Henderson Investors
9.99%
VR Adviser, LLC
7.01%
Invus Public Equities Advisors, LLC
6.84%
RTW Investments L.P.
6.06%
其他
54.60%
持股股东
持股股东
占比
Ikarian Capital LLC
15.50%
Janus Henderson Investors
9.99%
VR Adviser, LLC
7.01%
Invus Public Equities Advisors, LLC
6.84%
RTW Investments L.P.
6.06%
其他
54.60%
股东类型
持股股东
占比
Hedge Fund
44.91%
Investment Advisor/Hedge Fund
27.27%
Venture Capital
10.35%
Investment Advisor
9.67%
Research Firm
2.99%
Individual Investor
0.34%
其他
4.47%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
56
4.15M
90.85%
+1.27M
2025Q2
58
2.98M
71.83%
+986.76K
2025Q1
58
2.74M
66.20%
+755.49K
2024Q4
56
1.98M
58.13%
+213.72K
2024Q3
58
1.98M
66.48%
+633.55K
2024Q2
48
161.28K
18.23%
+129.16K
2024Q1
48
149.68K
17.63%
+121.80K
2023Q4
43
26.36K
16.08%
+6.23K
2023Q3
45
17.13K
13.16%
+882.00
2023Q2
48
14.32K
12.38%
-2.77K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Ikarian Capital LLC
967.60K
21.21%
+967.60K
--
Sep 30, 2025
Janus Henderson Investors
166.67K
3.65%
--
--
Jun 30, 2025
VR Adviser, LLC
98.56K
2.16%
-109.77K
-52.69%
Jun 30, 2025
RTW Investments L.P.
378.35K
8.29%
--
--
Jun 30, 2025
Dellora Investments LP
351.07K
7.69%
--
--
Mar 05, 2025
BVF Partners L.P.
339.55K
7.44%
--
--
Jun 30, 2025
Millennium Management LLC
233.71K
5.12%
+207.09K
+777.77%
Jun 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
DFA Dimensional US Sustainability Core 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
公告日期
类型
比率
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Dec 29, 2023
Merger
80→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
Jan 04, 2023
Merger
20→1
常见问题
Tenax Therapeutics Inc的前五大股东是谁？
Tenax Therapeutics Inc 的前五大股东如下：
Ikarian Capital LLC持有股份：967.60K，占总股份比例：21.21%。
Janus Henderson Investors持有股份：166.67K，占总股份比例：3.65%。
VR Adviser, LLC持有股份：98.56K，占总股份比例：2.16%。
RTW Investments L.P.持有股份：378.35K，占总股份比例：8.29%。
Dellora Investments LP持有股份：351.07K，占总股份比例：7.69%。
Ikarian Capital LLC持有股份：967.60K，占总股份比例：21.21%。
Janus Henderson Investors持有股份：166.67K，占总股份比例：3.65%。
VR Adviser, LLC持有股份：98.56K，占总股份比例：2.16%。
RTW Investments L.P.持有股份：378.35K，占总股份比例：8.29%。
Dellora Investments LP持有股份：351.07K，占总股份比例：7.69%。
Tenax Therapeutics Inc的前三大股东类型是什么？
Tenax Therapeutics Inc 的前三大股东类型分别是：
Ikarian Capital LLC
Janus Henderson Investors
VR Adviser, LLC
Ikarian Capital LLC
Janus Henderson Investors
VR Adviser, LLC
有多少机构持有Tenax Therapeutics Inc(TENX)的股份？
截至2025Q3，共有56家机构持有Tenax Therapeutics Inc的股份，合计持有的股份价值约为4.15M，占公司总股份的90.85%。与2025Q2相比，机构持股有所增加，增幅为19.03%。
哪个业务部门对Tenax Therapeutics Inc的收入贡献最大？
在--，--业务部门对Tenax Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
